Pharmacokinetics and pharmacodynamics of high dose melphalan in myeloma patients undergoing an autograft.
Not Applicable
Completed
- Conditions
- Multiple myelomaCancer - Myeloma
- Registration Number
- ACTRN12606000231549
- Lead Sponsor
- The Childrens Hospital at Westmead
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 140
Inclusion Criteria
All myeloma patients scheduled to receive high dose melphalan followed by an autologous transplant.
Exclusion Criteria
The only patients that will be exluded from the study are those unable to give informed consent.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method